Stoke Therapeutics (NASDAQ:STOK) had its price objective cut by JPMorgan Chase & Co. from $34.00 to $33.00 in a note issued to investors on Tuesday, BenzingaRatingsTable reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price would suggest a potential upside of 28.96% from the company’s current price.
Several other analysts also recently weighed in on the company. Zacks Investment Research raised Stoke Therapeutics from a “hold” rating to a “buy” rating and set a $23.00 target price for the company in a report on Wednesday, October 16th. HC Wainwright started coverage on Stoke Therapeutics in a research note on Friday, October 25th. They set a “buy” rating and a $30.00 price target on the stock. Cowen reaffirmed a “buy” rating on shares of Stoke Therapeutics in a research report on Thursday, August 15th. Finally, BTIG Research initiated coverage on Stoke Therapeutics in a research note on Tuesday, November 12th. They issued a “buy” rating and a $46.00 price objective for the company. Seven investment analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and a consensus price target of $35.17.
Shares of STOK opened at $25.59 on Tuesday. Stoke Therapeutics has a 1-year low of $19.21 and a 1-year high of $39.04. The company has a fifty day moving average of $25.03.
In other Stoke Therapeutics news, major shareholder Rtw Investments, Lp bought 31,560 shares of the firm’s stock in a transaction dated Tuesday, October 1st. The stock was acquired at an average price of $21.96 per share, for a total transaction of $693,057.60. Insiders bought 205,216 shares of company stock valued at $5,771,421 over the last ninety days.
A number of institutional investors and hedge funds have recently made changes to their positions in STOK. Cormorant Asset Management LP purchased a new stake in shares of Stoke Therapeutics in the second quarter valued at approximately $54,539,000. Perceptive Advisors LLC acquired a new stake in shares of Stoke Therapeutics in the second quarter valued at about $19,601,000. Janus Henderson Group PLC purchased a new stake in Stoke Therapeutics during the second quarter worth about $11,668,000. Price T Rowe Associates Inc. MD purchased a new stake in Stoke Therapeutics during the second quarter worth about $10,994,000. Finally, State Street Corp acquired a new position in Stoke Therapeutics during the third quarter worth about $2,987,000. 48.61% of the stock is currently owned by institutional investors.
About Stoke Therapeutics
Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001, to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc has a partnership with Invitae Corporation to offer epilepsy panel testing.
Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.